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Chemokines are required for leukocyte
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additionalMMP-2/9 activity specifically at
the border of the CNS parenchyma
strongly enhances this transmigration
process. Song et al. show that cytokines
derived from infiltrating leukocytes
regulate MMP-2/9 activity at the
parenchymal border, which differentially
modulates chemokine activities, thereby
accelerating leukocyte migration into the
CNS.
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Although chemokines are sufficient for chemotaxis
of various cells, increasing evidence exists for their
fine-tuning by selective proteolytic processing.
Using a model of immune cell chemotaxis into the
CNS (experimental autoimmune encephalomyelitis
[EAE]) that permits precise localization of immi-
grating leukocytes at the blood-brain barrier, we
show that, whereas chemokines are required for
leukocyte migration into the CNS, additional MMP-
2/9 activities specifically at the border of the CNS
parenchyma strongly enhance this transmigration
process. Cytokines derived from infiltrating leuko-
cytes regulate MMP-2/9 activity at the parenchymal
border, which in turn promotes astrocyte secretion
of chemokines and differentially modulates the ac-
tivity of different chemokines at the CNS border,
thereby promoting leukocyte migration out of the
cuff. Hence, cytokines, chemokines, and cytokine-
induced MMP-2/9 activity specifically at the inflam-
matory border collectively act to accelerate leuko-
cyte chemotaxis across the parenchymal border.
INTRODUCTION
Chemokines are central for migration of several cell types; how-
ever, their levels and efficacy of action depend on additional
factors, such as cytokines and/or their selective proteolytic pro-
cessing. Particularly in models of autoimmunity, T cell-derived
cytokines define the characteristics of different T cell subpopu-
lations and play decisive roles in shaping the microenvironment
within the target organ, which collectively regulate immune cell1040 Cell Reports 10, 1040–1054, February 24, 2015 ª2015 The Authinfiltration. Experimental autoimmune encephalomyelitis (EAE)
is a widely used T cell-mediated model for the early inflamma-
tory stages of multiple sclerosis (MS) that depends on a special
microenvironment at the blood-brain barrier (BBB). Due to a
unique double-basement membrane structure of cerebral blood
vessels (Sixt et al., 2001), EAE has proven to be a valuable
model for investigating the steps in leukocyte migration into
the CNS. Initial penetration of the BBB requires transmigration
of the endothelial monolayer and its underlying endothelial
basement membrane, followed by accumulation in the perivas-
cular space where leukocytes are retained for several days.
Within the perivascular cuff, leukocytes are reactivated and
the balance of effector versus regulatory T cell populations is
determined (Ko¨rner et al., 1997), which permits subsequent
transmigration of the parenchymal basement membrane and
glia limitans and infiltration of the CNS parenchyma. Only then
do disease symptoms become apparent, indicating that mi-
gration out of the perivascular cuff is a disease-limiting step
(Agrawal et al., 2006).
Effector T cell populations critical for the pathogenesis of EAE
include T helper type 1 (TH1) and interleukin-17 (IL-17)-producing
T helper (TH17) cells, which differ in their cytokine profiles and,
thereby, proinflammatory properties. TH1 cells are characterized
by secretion of tumor necrosis factor (TNF-a) and interferon-g
(IFN-g), whereas TNF-a and IL-17 are representative of the
TH17 cell lineage (Weaver et al., 2007), which is considered to
be a pro-encephalitogenic population. However, precisely how
these cytokines influence the different steps in immune cell
penetration of tissues remains inconclusive.
Data suggest that penetration of the endothelial and paren-
chymal barriers are independent steps involving distinct molec-
ular mechanisms. While several factors have been identified that
play important roles in penetration of the endothelial cell mono-
layer (Engelhardt, 2006) and its basement membrane (Sixt et al.,
2001; Wu et al., 2009), comparatively little is known about theors
subsequent penetration of the parenchymal border. Chemo-
kines such as CXCL12 have been shown to be required for hold-
ing T cells in the perivascular cuff, and its proteolytic degradation
by MMPs releases leukocytes to migrate into the CNS paren-
chyma (McCandless et al., 2006). TNF-a also has been im-
plicated in this step as TNF-a knockout (Tnf–/–) mice show
massively enlarged perivascular cuffs and delayed onset of dis-
ease symptoms (Ko¨rner et al., 1997). Although the precisemech-
anism of TNF-a action is not clear, differences in chemokine
profiles in the CNS of Tnf–/– mice compared to wild-type (WT)
littermates have been proposed to delay the initial leukocyte
penetration of the parenchymal barrier (Murphy et al., 2002). In
addition, in situ zymography has revealed matrix metalloprotei-
nase (MMP)-2 and MMP-9 activity at sites of leukocyte penetra-
tion of the parenchymal border (Agrawal et al., 2006). Young
MMP-9 knockout mice are partially resistant to EAE (Dubois
et al., 1999), while MMP-2 and MMP-9 double-knockout (DKO)
mice are completely resistant to disease development (Agrawal
et al., 2006), suggesting a central role for these MMPs in disease
induction.
In addition to CXCL12, several chemokines play a role in
leukocyte recruitment in EAE (Ransohoff, 2009), some of which
are constitutively expressed in the CNS parenchyma and upre-
gulated during EAE and others that are newly synthesized (Am-
brosini et al., 2005; Glabinski et al., 1995; Murphy et al., 2002).
However, CNS-specific chemokine expression never precedes
histopathological signs of EAE (Glabinski et al., 1995; Huang
et al., 2000), indicating that initial leukocyte infiltration into the
CNS is a prerequisite for the expression of chemokines. Proin-
flammatory cytokines secreted from infiltrating cells, including
TNF-a, IFN-g, and IL-17, can directly influence chemokine levels
by inducing mRNA expression (Murphy et al., 2002) and stability
(Hartupee et al., 2007), but they also can have indirect effects by
modulating protease levels and activities, including those of
MMPs, which in turn can alter chemokine activation or inactiva-
tion and their expression (Corry et al., 2002; McQuibban et al.,
2000; Van den Steen et al., 2000).
Using bone marrow (BM) chimeric mice lacking immune-cell
or tissue-resident sources of MMP-2 and MMP-9 or TNF-a
in EAE experiments combined with in vitro studies, we show
here that inflammatory cytokines, chemokines, and activated
MMP-2 and MMP-9 act in concert at the parenchymal border
to determine whether or not leukocyte infiltration into the CNS
parenchyma occurs.
RESULTS
Mice Lacking MMP-2 and MMP-9 in Immune and
Tissue-Resident Cells Have Enlarged Perivascular Cuffs
To distinguish between infiltrating leukocyte and CNS-resident
sources of the gelatinases, WT, Mmp2/ or Mmp9/, and
DKO recipients carrying WT BM, and therefore WT leukocytes,
were actively induced for EAE. Conversely, DKO BM was trans-
ferred to WT recipients to generate mice lacking a leukocyte
source of MMP-2/9, and EAE was actively induced. In the
absence of a tissue-resident or leukocyte source of MMP-2
and MMP-9, the appearance of EAE symptoms was delayed
and disease symptoms were less severe than in WT or single-Cell RKO chimeric mice (Figure 1A), indicating that MMP-2/9 from
both leukocytes and resident cells contribute to EAE induction
and severity.
No differences were measured in numbers of CD45+ leuko-
cytes, CD4+ or CD8+ T cells, and CD11b+ macrophages in the
CNS during EAE in any of the chimeric mice carrying WT BM.
Only WT mice carrying DKO BM showed lower numbers of all
immune cells (Figures 1B, 1C, S1A, and S1B), suggesting an
impaired immune response in the absence of leukocyte-derived
MMP-2 and MMP-9. Since these chimeric mice develop EAE
symptoms, T cell priming in the periphery may be less efficient
than when MMPs are expressed by immune cells but acti-
vated effector T cells can be generated. This was confirmed by
in vitro experiments that revealed a reduced antigen-specific
response of DKO CD4+ T cells (Figure S1C), but an absence of
defects in anti-CD3-induced T cell proliferation (Figure S1D).
Immunofluorescence staining of brain and spinal cord sec-
tions, using antibodies to pan-laminin and CD45 to visualize
the endothelial and parenchymal basement membranes and
infiltrating leukocytes, suggested enlarged perivascular cuffs
in mice lacking an immune-cell or tissue-resident source of
MMP-2 and MMP-9 (Figure 1D). Stereological analyses,
involving MRI determination of tissue volumes (Figure S1E) and
subsequent calculation of cuff numbers and cuff area/brain or
spinal cord using serial sections throughout the entire tissue
stained for pan-laminin and CD45, revealed that mice lacking a
leukocyte or tissue-resident source of MMP-2 and MMP-9 had
fewer but larger cuffs at EAE onset (Figures 1E and 1F). At
peak EAE, when significant numbers of leukocytes had pene-
trated the parenchymal border, there were fewer cuffs but they
remained enlarged in DKO mice carrying WT BM (Figures S1F
and S1G), suggesting a more prominent role of CNS-derived
MMPs for penetration of the parenchymal border.
Enlarged cuffs without differences in total immune cell in-
filtration suggests either enhanced leukocyte migration into or
reduced migration out of the cuff. Transfer of CD45.1+ WT
MOG35–55-specific T cells to CD45.2
+ WT, Mmp2–/–, Mmp9–/–,
or DKO recipients and quantification of CD45.1+ T cells in the
CNS of recipient mice at day 3 after transfer, before proliferation
had commenced (Wu et al., 2009), revealed equal numbers of
donor T cells in all recipients (Figures S2A and S2B). This sug-
gests that the enlarged cuffs in mice lacking a resident source
of MMP-2 and MMP-9 was due to reduced migration out of
the cuff.
In both brains and spinal cords of mice lacking a leukocyte
or tissue-resident source of MMP-2 and MMP-9, fewer cuffs
showed leukocyte penetration at EAE onset compared to peak
(Figure S3A). Immunohistochemistry for myelin basic protein re-
vealed no demyelination (Figure S3B) nor detectable MMP-2/9
activity by in situ zymography surrounding cuffs until leukocyte
penetration had occurred and EAE symptoms were apparent
(Figures 1D and S3C; Agrawal et al., 2006).
Mice Lacking T Cell-Derived TNF-a Also Have
Enlarged Cuffs
Enlarged perivascular cuffs also have been reported in Tnf/
mice induced for EAE (Ko¨rner et al., 1997). As T cell-derived
TNF-a has been shown to be responsible for this phenotypeeports 10, 1040–1054, February 24, 2015 ª2015 The Authors 1041
Figure 1. Leukocyte and Tissue-Resident
Sources ofMMP-2 andMMP-9 Are Required
for EAE
(A) Time course of EAE in WT, Mmp2/,
Mmp9/, and MMP-2 and MMP-9 DKO mice,
carrying WT BM, and WT mice carrying DKO BM.
(B and C) Flow cytometry quantification of total
donor CD45+ cells in the CNS at onset (days
12–15) and peak EAE (day 20). Data in (A–C) are
means ± SEM; each point n = 12.
(D) CNS sections from WT mice carrying WT or
DKO BM and DKOmice carrying WT BM at day 17
EAE immunofluorescently stained for CD45+ leu-
kocytes and pan-laminin, to define endothelial and
parenchymal basement membranes, and corre-
sponding gelatin in situ zymography for MMP-2
and MMP-9 activity (Gel).
(E and F) Stereological analyses at EAE onset for
(E) cuff numbers and (F) sizes. Cuff numbers are
means ± SEM of four experiments, with three
mice/group; cuff areas are all values measured.
Scale bars represent 80 mm. *p < 0.05,**p < 0.01,
***p < 0.001. See also Figures S1–S3.(Murphy et al., 2002), we adoptively transferred encephalito-
genic Tnf/ T cells to WT recipients and examined cuff sizes
in correlation with MMP-2/9 activity. EAE was delayed and
reduced in severity in mice lacking T cell-derived TNF-a (Fig-
ure 2A), as observed in Tnf/mice induced for EAE (Figure S4A;
Ko¨rner et al., 1997). Immunofluoresence staining and stereologi-
cal analyses revealed similarly enlarged cuffs in TNF-a-deficient
mice (Figures 2B–2D and S4B–S4F), as observed in the MMP-
2/9 BM chimeric mice, with equivalent numbers of immune cells
at onset and peak EAE (Figures S4G and S4H), which correlated
with no detectable MMP-2 andMMP-9 activity using gel zymog-
raphy and in situ zymography (Figure 2B). At peak EAE, when
considerable numbers of leukocytes had penetrated the paren-
chymal border, MMP-2/9 activity was detectable and cuff sizes
were reduced (Figures 2B–2D and S4B–S4F).1042 Cell Reports 10, 1040–1054, February 24, 2015 ª2015 The AuthorsT Cell-Derived TNF-a/IFN-g
Ratios Control MMP-9 Expression
at the BBB
To investigate whether a causal relation-
ship exists between TNF-a and MMP-2/
MMP-9 activity at the BBB, we examined
cytokine levels in the CNS and the source
of MMPs at the parenchymal border.
After EAE induction, Tnf/ mice showed
significantly increased proportions of
CD4+IFN-g+ cells in the CNS (Figure 2E),
draining lymph nodes (LNs) and spleens
(Figure S4I) compared to WT mice.
Elevated levels of IFN-g was corrobo-
rated by ELISA of CNS extracts of WT
and Tnf–/– mice (Figure 2F). Accord-
ingly, conditioned media from cultured
MOG35–55-specific Tnf
–/– and WT CD4+
T cells contained identical levels of IL-4,
IL-10, IL-6, IL-17, and IL-1a, but elevatedIFN-g in Tnf–/– samples (Figure S4J). Hence, Tnf–/– CD4+ T cells
not only lack TNF-a, but also have elevated IFN-g levels
throughout the disease course (Figure S4K).
Previous studies have identified MMP-9 secretion by T cells
(Dubois et al., 1999) and MMP-2 and MMP-9 by macrophages
(Agrawal et al., 2006). In situ hybridization of WT mice carrying
DKO BM, and hence no immune-cell source of MMP, showed
that astrocytes at the BBB also can express MMP-9, but only af-
ter EAE induction (Figure 3A). This was confirmed using qPCR,
gel zymography, and ELISA of cultured astrocytes, revealing
constitutive expression of pro- and activated MMP-2 and upre-
gulation of pro- and activated MMP-9 by TNF-a and, to a lesser
extent, by IL-17 and inhibition by IFN-g (Figures 3B–3D). A similar
trend but with milder effects was observed for MMP-2 (Figures
3B–3D). These results are consistent with the reported effects
Figure 2. T Cell-Derived Cytokines Regulate Leukocyte Penetration of the Parenchymal Border
(A) Time course of EAE after passive transfer of WT encephalitogenic T cells to WT and Tnf–/– recipients, or Tnf–/– encephalitogenic T cells to WT recipients. Data
are means ± SEM from three experiments with six mice/group.
(B) Immunofluorescence staining of day 17 EAE CNS sections for pan-laminin and CD45 and corresponding gelatin in situ zymography for MMP-2 and MMP-9
activity (Gel). Scale bars represent 80 mm.
(C andD) Stereological analyses at EAE onset for (C) cuff numbers and (D) sizes, showing enlarged cuffs inmice lacking a T cell source of TNF-a. Cuff numbers are
means ± SEM of three experiments, with three mice/group; cuff areas are all values measured.*p < 0.05, ***p < 0.001.
(E and F) (E) Flow cytometry for intracellular cytokine staining in CD4+ T cells from CNS of WT and Tnf–/– mice at day 20 after EAE induction and (F) corresponding
total cytokine levels in CNS extracts measured by ELISA. Data are means ± SEM from three experiments, with triplicates/experiment. Values are means of three
to four experiments with triplicates/time point or treatment ± SEM. **p < 0.01. See also Figures S4 and S5.
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Figure 3. T Cell-Derived Inflammatory Cytokines Regulate Astrocyte Expression of MMP-2 and MMP-9
(A) In situ hybridization of MMP-9 cDNA on brain sections fromWT mice carrying WT or DKO BM at days 15–17 of EAE counter-stained for the astrocyte marker
GFAP (red) and for DAPI (blue) to show immune cell accumulations.
(B–D) (B) qPCR shows MMP-2 and MMP-9 mRNA expression by WT astrocytes, which is enhanced by TNF-a and IL-17 and reduced by IFN-g, and is confirmed
at the protein level by (C) gelatin gel zymography and (D) ELISA of concentrated, pre-purified conditioned media samples. Scale bar represents 30 mm. *p < 0.05,
**p < 0.01, ***p < 0.001.of cytokines on MMP-2 and MMP-9 expression in other tissues
(Rosenberg, 2002). Taken together, the data suggest that
MMP-9 secretion by astrocytes at the BBB is enhanced by
T cell-derived TNF-a/IL-17 and inhibited by IFN-g.1044 Cell Reports 10, 1040–1054, February 24, 2015 ª2015 The AuthMMPs Are Required for Leukocyte Chemotaxis
out of the Cuff
As chemokines are required for attracting T lymphocytes into
the CNS parenchyma during EAE, we tested the chemotacticors
Figure 4. MMP-2/9 and Cytokines Are Required for Chemokine Secretion in the CNS
(A–D) Chemotactic potential of CNS extracts isolated at peak EAE (day 20) from (A) MMP-2/9 DKO chimeric mice and from (B) mice adoptively transferred
with encephalitogenic WT or Tnf/ T cells and (C and D) corresponding chemokine levels measured by ELISA in CNS extracts at EAE onset and peak. Data
for CXCL12 are for full-length + cleaved chemokine and cleaved chemokine only (CXCL12 5-67). Data are means of four experiments with six mice/group ± SEM.
*p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S5.potential of CNS extracts collected at peak EAE from MMP BM
chimeric mice and from Tnf–/– adoptive transfer experiments.
CNS extracts were added to the bottom chamber of a transwell
system and primary CD4+ encephalitogenic T cells were placed
in the top chamber. Transmigrated cells were counted at 6 hr.
CNS extracts from WT or Mmp2–/– and Mmp9–/– chimeric mice
had approximately the same chemotactic potential, which was
signficantly reduced in CNS extracts from mice lacking a tis-Cell Rsue-resident source of MMP-2 andMMP-9 (Figure 4A) or lacking
a T cell source of TNF-a (Figure 4B). To identify the missing
chemotactic factor/s, the major chemokines implicated in EAE
(CCL2, CCL3, CCL5, CCL20, CXCL10, and CXCL12) (Glabinski
et al., 2005; Huang et al., 2000) were measured in CNS extracts
at early and peak EAE. Significantly lower levels of all chemo-
kines were measured in mice lacking tissue-resident sources
of MMP-2 and MMP-9 or T cell-derived TNF-a, with theeports 10, 1040–1054, February 24, 2015 ª2015 The Authors 1045
Figure 5. T Cell-Derived Cytokines Enhance Astrocyte Chemotactic Potential Only when MMP-2 or MMP-9 Is Present
(A) Transmigration of encephalitogenic T cells in response to conditioned media from irradiated WT,Mmp2/,Mmp9/, or DKO astrocytes in the presence or
absence of activated MMP-2 or MMP-9.
(B–D) (B) Chemotactic potential of WT astrocyte-conditioned medium is enhanced by treatment with MMP-2 and MMP-9 or the progelatinase activator MMP-3,
but not by MMPs-1, -7, or -8, and (C) reduced by inhibition of MMP activity by 50 or 150 nMMOBSAM; (D) corresponding chemokine levels in conditioned media
of WT astrocytes treated with activated MMP-2 or MMP-9 or 50 nM MOBSAM.
(legend continued on next page)
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exception of CXCL12, which was elevated at peak EAE in all sit-
uations (Figures 4C, 4D, S5A, and S5B). As MMP-2 and MMP-9
inactivate CXCL12 (Vergote et al., 2006), we also measured
cleaved inactivated CXCL12, revealing significantly reduced
levels in mice lacking MMP-2 and MMP-9 or T cell-derived
TNF-a, suggesting higher levels of full-length CXCL12 (Figures
4C and 4D).
Astrocyte-Derived MMP-2 and MMP-9 Enhance
T Cell Chemotaxis
As astrocytes express chemokines (Ambrosini et al., 2005; Gla-
binski et al., 1995; Kim et al., 2014) and, as shown here, MMP-2
and MMP-9, and they are strategically located at the paren-
chymal border, we utilized cultured astrocytes from WT and
DKO mice to examine whether a relationship exists between
MMPs and chemotactic potential. Conditioned media from
WT-, Mmp2–/–-, Mmp9–/–-, or DKO-cultured astrocytes were
used as chemoattractants in the lower chamber of a transwell
system, and primary encephalitogenic T cells were placed in
the upper chamber. Transmigrated cells were measured by
flow cytometry after 6 hr. WT, Mmp2–/–, and Mmp9–/– astro-
cyte-conditioned media showed a basal chemotactic potential
not present in DKO-conditioned medium (Figure 5A), which
was enhanced by the addition of activated MMP-2, MMP-9, or
MMP-3, but not other MMPs (Figure 5B). MMP-3 activates
MMP-2 and MMP-9 (Ogata et al., 1992) and thereby probably
increased the activated fraction of endogenous MMP-2 and
MMP-9 present in the astrocyte-conditioned medium. Con-
versely, the basal chemotactic activity of WT astrocyte-condi-
tioned medium was inhibited by MOBSAM, a chemical inhibitor
that shows concentration-dependent inhibition of specific
MMPs (Matsumura et al., 2005). Low doses of MOBSAM
(10 nM) inhibit MMP-2 activation only, whereas 50 nMMOBSAM
inhibits both MMP-2 and MMP-9 and >100 nM inhibits MMP-8,
MMP-12, and MMP-13 (Matsumura et al., 2005). As no suppres-
sion of astrocyte chemotactic activity was observed at 10 nM
MOBSAM,whereas 50 nMand 150 nM showed the same degree
of inhibition (Figure 5C), this indicates that MMP-2 and MMP-9
are sufficient for regulation of the astrocyte-derived chemotactic
activity. The data suggest that astrocytes could be a source of
chemotactic factors for encephalitogenic T cells, the activity of
which is enhanced by MMP-2 or MMP-9.
ELISA was used to investigate whether this chemotactic
potential correlated with chemokine levels in the conditioned
media. WT astrocyte-conditioned medium contained CCL2,
CCL3, CCL5, CCL20, and CXCL10 (Figure 5D). CXCL12 was
not detectable and is considered to be secreted by perivascular
cells (McCandless et al., 2006). Treatment of WT astrocytes with
activatedMMP-2 orMMP-9 increased the levels of all detectable
chemokines, while inhibition of MMP activation with 50 nM
MOBSAM had a suppressive effect (Figure 5D), consistent with(E and F) (E) Chemotactic activity ofWT astrocytes is enhanced by coincubationw
effects. TNF-a plus IL-17 have additive effects and IFN-g inhibits the enhanced
(G) DKO astrocyte-conditioned medium has reduced chemotactic potential, whi
(H) Chemokine levelsmeasured by ELISA in conditionedmedia fromWT or DKO as
three times using different astrocyte preparations, with triplicates/treatment in ea
also Figure S6.
Cell Rthe transmigration data and suggesting endogenous MMP
expression by astrocytes.
Pro- and Anti-Inflammatory Cytokines Modulate T Cell
Chemotaxis in a MMP-Dependent Manner
Since TNF-a and IFN-g affect MMP levels, we investigated the
chemotactic potential of astrocyte-conditioned media in the
presence and absence of TNF-a or IFN-g, and correlated this
with measurable chemokine levels. To mimic the in vivo situa-
tion, astrocytes were coincubated with primary TH1 or TH17
cells, and the chemotactic potential of the conditioned media
was tested. CFSE-labeled CD4+ T cells were added to the upper
chamber of a transwell system to distinguish them from T cells
coincubated with astrocytes, and transmigrated CFSE+ cells
were quantified by flow cytometry after 12 hr. The chemotactic
activity of the astrocytes was significantly enhanced by coincu-
bation with WT TH17 cells, which secrete TNF-a and IL-17, while
coculture with TH1 cells, which secrete TNF-a and IFN-g, had lit-
tle effect. TH17 or TH1 cells alone had no effect (Figure 5E).
Enhanced chemotaxis also was measured when WT astrocytes
were stimulated with TNF-a or IL-17, with TNF-a plus IL-17 hav-
ing mild additive effects (Figure 5F). By contrast, conditioned
medium from IFN-g-treated astrocytes inhibited both the basal
chemotactic activity of astrocyte-conditioned medium and sup-
pressed the enhanced chemotactic effects of TNF-a and IL-17
(Figure 5F). In the absence of astrocytes, cytokines alone had
no effect on T cell transmigration (Figure 5F). When the same ex-
periments were performed with DKO astrocyte-conditioned me-
dia, the basal chemotactic potential and the enhancing effects of
TNF-a and IL-17 were suppressed (Figure 5G), and were
rescued by the addition of activated MMP-2 or MMP-9
(Figure 5A).
Corresponding measurement of EAE-relevant chemokines
in the cytokine-treated astrocyte-conditioned media revealed
the absence of a strict correlation between chemokine levels
and measured chemotaxis. While TNF-a and IL-17 both
enhanced transmigration, TNF-a but not IL-17 increased che-
mokine levels, and IFN-g, which suppressed transmigration,
did not consistently reduce chemokine levels (Figures 5H
and S6). These data support a role for TNF-a alone or in
combination with IL-17 in inducing chemokine secretion by
astrocytes, but also reinforces the pivotal role of MMP-2
and MMP-9 on the efficacy of astrocyte-derived chemotactic
factors. Consistent with transmigration data, DKO astrocyte-
conditioned medium contained significantly lower levels of
all chemokines and a reduced response to TNF-a, IL-17,
and IFN-g (Figure 5H). Together with the strong upregulation
of chemokine levels in response to MMP-2/9 treatment of as-
trocytes, in particular CXCL10 (Figure 5D), this suggests that
MMP-2 and MMP-9 may promote chemokine release by
astrocytes.ith TH17 but not TH1 cells and by (F) TNF-a or IL-17, while IFN-g has suppressive
chemotactic effects of TNF-a and IL-17.
ch is not affected by proinflammatory chemokines.
trocytes treatedwith proinflammatory cytokines. Experiments were performed
ch experiment. Data are means ± SEM. *p < 0.05,**p < 0.01,***p < 0.001. See
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Figure 6. Signaling Pathway of MMP-2- and
MMP-9-Induced Chemokine Secretion by
Astrocytes
(A) Western blots for AKT/pAKT, p65/p-P65, and
PTEN in cell extracts from untreated and TNF-a-,
MMP-2-, and MMP-9-treated WT astrocytes.
b-Tubulin is the loading control.
(B) Quantification of qPCR data for Notch-1-
induced transcription factors, Hes1 and Hes5, in
untreated and MMP-2- and MMP-9-treated WT
and DKO astrocytes. Data are expressed as fold
differences over WT levels and are means ± SEM
of three to four experiments with triplicates/treat-
ment.
(C) Flow cytometry shows loss of Notch-1
expression on Notch-loxP astrocytes after Cre-
recombinase treatment.
(D and E) (D) Conditioned media from Notch1/
astrocytes show reduced chemotactic potential
compared to WT astrocytes, (E) significantly re-
duced chemokine levels, and absence of MMP-2-
or MMP-9-induced upregulation of chemokines.
Data are means ± SEM of three to four experi-
ments with three to six replicates. *p < 0.05,**p <
0.01, ***p < 0.001. See also Figure S7.MMP-2 and MMP-9 Induce Chemokine Expression
We therefore investigated whether MMP-2 and MMP-9 of astro-
cytes impact on the major pathway associated with chemokine
expression, namely PI3K/p-AKT/necrosis factor kB (NF-kB) (Qui-
nones et al., 2008; Thompson and Van Eldik, 2009; van Loo et al.,
2006). Western blots revealed that MMP-2- or MMP-9-treated
astrocytes had increased levels of phosphorylated AKT and p-
P65 (Figure 6A), suggesting increased NF-kB translocation to
thenucleus.Similar effectswereobservedwithTNF-a (Figure6A),
which is known to induce chemokine expression via NF-kB
signaling (Quinones et al., 2008; Thompson and Van Eldik, 2009).1048 Cell Reports 10, 1040–1054, February 24, 2015 ª2015 The AuthorsTo determine how MMPs could
enhance NF-kB signaling, we turned to
two known cell-surface MMP substrates
on astrocytes: (1) dystroglycan, which an-
chors astrocyte endfeet to the paren-
chymal basement membrane (Agrawal
et al., 2006); and (2) Notch-1, which is
important for astrocyte development
(Cau and Blader, 2009). Dystroglycan
can signal via PI3K/p-AKT in skeletal
muscle, but only when anchored to one
of its ligands, laminin (Langenbach and
Rando, 2002). As MMP-2 and MMP-9
cleave dystroglycan on astrocytes, dis-
connecting it from its ligands in the paren-
chymal basement membrane (Agrawal
et al., 2006), it is unlikely to be associated
with increased NF-kB signaling. By
contrast, cleavage of Notch-1 by MMP-
9 can lead to the inhibition of PTEN,
thereby upregulating PI3K/p-AKT and
NF-kB signaling (Garg et al., 2010). West-ern blots revealed inhibition of PTEN by MMP-2 or MMP-9 treat-
ment of WT astrocytes (Figure 6A), and a corresponding upregu-
lation of Notch-1-specific transcription factors, Hes1 and
Hes5 (Figure 6B). DKO astrocytes showed reduced Hes1 and
Hes5 expression, which was rescued by the addition of MMP-
2 or MMP-9 (Figure 6B). Notch-1/ astrocytes (Figure 6C)
showed reduced basal chemotactic activity that was not
rescued by MMP-2 or MMP-9 (Figure 6D), and showed no upre-
gulation of chemokines in response to MMP-2 or MMP-9 treat-
ment (Figure 6E). Control experiments with dystroglycan KO
(Dag/) astrocytes (Figure S7A) showed no difference
Figure 7. Differential Localization of Intact and MMP-Cleaved
CXCL12, CCL3, and CXCL10 during EAE
(A) Brain sections from WT mice carrying WT (WT to WT) or DKO BM (DKO to
WT) and DKO mice carrying WT BM mice (WT to DKO) were immuno-
fluorescently stained at peak EAE for full-length and cleaved CXCL12 and pan
laminin, revealing concentration within cuffs.
(B) Consecutive sections were stained for pan-laminin and cleaved CXCL12
only (CXCL12 5-67), revealing cleaved CXCL12 in the CNS parenchyma of WT
to WT BM chimeras only.
(C and D) (C) Staining of WT brains at peak EAE for pan-laminin and CCL3
revealed expression only in cuffs, while (D) triple staining for pan-laminin,
Cell Rcompared toWT astrocytes in basal chemotactic potential, T cell
transmigration in response to MMP-2 or MMP-9 (Figure S7B), or
upregulation of chemokines (Figure S7C). Hence, MMP-2 and
MMP-9 may stimulate Notch-1 signaling in astrocytes, leading
to the inhibition of PTEN and subsequent induction of p-AKT/
NF-kB-signaling pathways and enhanced chemokine secretion.
MMP-2 and MMP-9 Also Modulate Chemokine
Availability at the Parenchymal Border
MMP-2 and MMP-9 also can modulate chemokine activity or
availability by selective cleavage (Van den Steen et al., 2000,
2003). While this is likely to occur in EAE, it is technically impos-
sible to prove as it requires quantities of chemokines and their
fragments for detection that cannot be extracted from the low
numbers of small perivascular cuffs. We therefore analyzed the
in vivo localization of key EAE chemokines in perivascular cuffs
and at the parenchymal border using the antibodies available
(CXCL12, CCL3, and CXCL10) in immunofluorescence confocal
microscopy. CCL2, a further critical EAE chemokine that is inac-
tivated by MMPs (McQuibban et al., 2002), was not investigated,
as it has been extensively studied by others showing broad dis-
tribution in the cuff and CNS parenchyma (Paul et al., 2014).
Since CXCL12 is inactivated byMMP-2 andMMP-9 (McQuibban
et al., 2001), we employed an antibody that recognizes
full-length and cleaved CXCL12, and another antibody that
recognizes only cleaved, inactive CXCL12 (CXCL12 5-67) (Ver-
gote et al., 2006). Triple staining for pan-laminin, CD45, and
CXCL12 antibodies localized CXCL12 within cuffs and in the sur-
rounding CNS parenchymal at onset and peak EAE (Figure 7A).
Staining for cleaved CXCL12 demonstrated its localization in
the CNS parenchyma only (Figure 7B), indicating that cleavage
not only inactivates CXCL12, but also releases it from local reten-
tion, as reported by others (De La Luz Sierra et al., 2004). In mice
lacking an immune-cell or tissue-resident source of MMPs,
staining with the antibody to full-length + cleaved CXCL12 was
restricted to the perivascular cuffs, with little or no signal for
cleaved CXCL12 (Figure 7B).
Staining for CCL3 was restricted to the perivascular cuffs (Fig-
ure 7C), while CXCL10 occurred mainly in the CNS parenchymal
surrounding cuffs and was detected only upon leukocyte pene-
tration of the parenchymal border (Figure 7D). Double staining
with GFAP revealed its localization close to astrocytes (Fig-
ure 7D), as previously reported (Carter et al., 2007). Staining for
CCL3 and CXCL10 were not altered in mice lacking MMPs (not
shown).
CXCL12 and CCL3 are inactivated by MMP-2 and MMP-9
(McQuibban et al., 2001; Vergote et al., 2006). CXCL10 is
cleaved byMMP-9 (Van den Steen et al., 2003). However, the ef-
fect of cleavage on its chemotactic activity has not been re-
ported. We therefore tested whether the chemotactic effect ofCXCL10, and GFAP showed CXCL10 in the CNS parenchyma close to
astrocytes. Scale bars in (A–D) represent 40 mm.
(E) Transmigration of primary encephalitogenic T cells in response to CXCL10
or CXCL12 alone or together, in the presence and absence of MMP-2 or
MMP-9. Transmigration in response to CCL21 ± MMP-2 or MMP-9 are con-
trols. Data are means ± SEM of three experiments with triplicates/treatment.
**p < 0.01, ***p < 0.001.
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CXCL10 for encephalitogenic T cells is altered by MMP-2/9
treatment using a transwell system. To mimic the in vivo situa-
tion, CXCL12 and CXCL10 were added alone or together, in
the presence or absence of MMP-2 or MMP-9. Comparisons
were made with CCL21, as an example of a chemokine that is
not cleaved by MMPs. MMP-2 or MMP-9 treatment of CXCL12
significantly reduced its chemotactic potential but had no effect
on CXCL10, while CXCL12 plus CXCL10 had additive effects
that were reduced to levels measured with CXCL10 alone in
the presence of MMP-2 or MMP-9 (Figure 7E).
Hence, MMP-2/9 derived from infiltrating cells or CNS-resi-
dent cells can inactivate CXCL12 and CCL3, releasing inacti-
vated CXCL12 into the CNS parenchyma and permitting infil-
trating T cells to respond to other chemokines in the CNS
parenchyma, such as CXCL10, which are not affected by the
MMPs.
DISCUSSION
Leukocyte penetration of the parenchymal border is a rate-
limiting step in the induction of EAE symptoms (Agrawal et al.,
2006; Toft-Hansen et al., 2006). We showed here that both im-
mune-cell and tissue-resident sources of MMP-2 and MMP-9
are required for this step and act specifically at the parenchymal
border to promote leukocyte migration out of the perivascular
cuff. We showed that the balance of leukocyte-derived inflam-
matory cytokines, TNF-a versus IFN-g, regulate mainly MMP-9
secretion and activation by astrocytes at the parenchymal
border, which can impact on levels and/or activity of chemokines
that attract the encephalitogenic T cells into the CNS to induce
EAE symptoms. TNF-a and IL-17 promote MMP-9, and to a
lesser extent MMP-2, secretion and activation, while IFN-g acts
as a negative regulator of their secretion and activation, as re-
ported in other systems (Di Girolamo et al., 2006; Ho et al., 2008).
In the absence of a CNS-resident source of MMP-2 and
MMP-9, immune cell migration to theCNS and into the perivascu-
lar cuff was not altered. However, cuffs were larger and penetra-
tion of the parenchymal border and onset of disease symptoms
were significantly delayed, which correlated with significantly
lower levels of most of the EAE-relevant chemokines in the
CNS, with the notable exception of CXCL12, and reduced clinical
symptoms. This is consistent with previous reports that CNS-
specific chemokine mRNA expression never precedes histo-
logical signs of EAE (Huang et al., 2000), and that initial leukocyte
infiltration into the CNS is a prerequisite for intrathecal expression
of chemokines (Glabinski et al., 1995). The initial recruitment of
T cells to the CNS is likely to be controlled by CXCL12, which
has been shown by others to hold immune cells in the perivascu-
lar cuff (McCandless et al., 2006), and which we show here is pre-
sent in its intact form only within the perivascular cuff.
We propose that once the right balance of Th1/Th17 cells in
the perivascular cuff is reached, and thereby the ratio of TNF-a
and IL-17 versus IFN-g is elevated, secretion of mainly activated
MMP-9 by astrocytes at the parenchymal border is enhanced.
The critical role of proinflammatory cytokines released from infil-
trating T cells in this step was demonstrated by transfer of
encephalitogenic Tnf/ T cells to WT recipients, also resulting
in enlarged perivascular cuffs and delayed onset of EAE symp-1050 Cell Reports 10, 1040–1054, February 24, 2015 ª2015 The Authtoms, reduced CNS chemokine levels, and, most importantly,
suppressed gelatinase activity, as observed in mice lacking a
resident MMP-2/9 source. Apart from the absence of TNF-a,
we show that Tnf/ T cells have significantly elevated IFN-g
levels, but otherwise normal levels of other cytokines, reinforcing
that it is not just the absence of TNF-a but rather the balance of
different cytokines that modulates MMP secretion and activity at
the inflammatory front.
We demonstrated a pivotal role for MMP-2 and MMP-9 ac-
tivity, rather than chemokine levels per se, in promoting T cell
migration. Conditioned medium from WT astrocytes constitu-
tively expressed pro-MMP-2 and activated MMP-2 and low
levels of pro-MMP-9, which correlated with a basal chemotactic
potential that was absent in DKO astrocyte-conditioned medium
or when MMP activation was chemically inhibited. This con-
stitutive expression of MMP-2 in the brain (Rosenberg, 2002)
probably accounts for leukocyte recruitment during immune sur-
veillance and at EAE induction. However, under inflammatory
conditions we showed that TNF-a strongly upregulates not
only chemokine expression by astrocytes (Ambrosini et al.,
2005), but also astrocyte MMP-9, and to lesser extent MMP-2,
expression and activation, which might enhance chemotactic
potential, but only when the astrocytes are capable of secreting
active MMP-2 or MMP-9. This is consistent with published data
that upregulation of chemokines by intracerebral injection of
TNF-a is not sufficient to cause accumulation of leukocytes in
the CNS (Glabinski et al., 2003).
By contrast, the effects of IL-17 and IFN-g on chemokine
secretion varied and did not correlate with their enhancing and
suppressive effects, respectively, on T cell chemotaxis. Rather,
gel zymography, ELISA, and qPCR suggested that IFN-g also
can suppress secretion and activation of MMP-9, as reported
previously (Di Girolamo et al., 2006), while IL-17 synergizes with
TNF-a to induce both chemokine secretion and MMP expres-
sion/activation, and importantly compensates for TNF-a in its
absence, as observed in the Tnf/ mice. These data are consis-
tent with the previously reported moderate effects of IFN-g on
chemokine secretion by astrocytes and with EAE data from
Ifng–/– mice, which have exacerbated disease symptoms but
reduced expression of several key EAE chemokines, including
CXCL10, CCL5, and CCL2 (Carter et al., 2007; Tran et al.,
2000), and only moderate upregulation of CCL3 and CCL1
(Tran et al., 2000). The fact that ablation of astrocyte-derived
MMP-2 and MMP-9 activity, either chemically (MOBSAM) or via
the use of DKO astrocytes, also significantly reduced the chemo-
tactic capacity of astrocytes, and that this could not be reversed
by cytokine treatment but only byMMP-2 or MMP-9 substitution,
suggests a key role for the MMPs in chemotaxis. Apart from as-
trocytes, other sources of MMPs, such as microglial or perivas-
cular cells (McCandless et al., 2006; Meiron et al., 2008), cannot
be excluded andmay contribute in vivo. In addition, immune cells
also can contribute to MMP-2 and MMP-9 at the parenchymal
border, as suggested by the EAE experiments performed with
DKO mice carrying WT BM.
MMP-2 and MMP-9 can promote early leukocyte migration
across the parenchymal border in several ways, including selec-
tive cleavage to modulate chemokine activity and/or availability
(Van den Steen et al., 2000, 2003) or promotion of chemokineors
secretion or release by astrocytes. Our data suggest that both
occur in EAE. It is impossible in our model to define precisely
which chemokines are affected in which way by the MMPs,
due to the limitations of even the most sophisticated mass spec-
trometry technologies for quantitative analysis of chemokines
and their fragments in the small inflammatory foci, and due to
the limited availibility of reagents for in vivo chemokine detection.
However, this is not the critical point, but rather that MMP-2 or
MMP-9 is essential at the inflammatory front and can modulate
EAE-relevant chemokines by cleavage and/or induction of their
expression, which impacts on whether or not leukocytes can
breach the inflammatory front. We demonstrated that one way
in which MMP-2 and MMP-9 may induce chemokine expression
by astrocytes is via activation of the AKT/NF-kB-signaling path-
way (Quinones et al., 2008; Thompson and Van Eldik, 2009) in a
Notch-1-dependent manner. Notch-1 is expressed by astro-
cytes (Cau and Blader, 2009) and is cleaved by MMP-9 (Garg
et al., 2010), and possibly also MMP-2, thereby resulting in the
inhibition of PTEN and activation of the Akt/NF-kB axis (Garg
et al., 2010; van Loo et al., 2006). However, other pathways
are not excluded and require investigation.
A role for MMP-2 and MMP-9 in modulating the activity or
availability of chemokines acting on infiltrating leukocytes is sup-
ported by the observation that CXCL12 levels were significantly
elevated in mice lacking either an immune-cell or tissue-resident
source of MMP-2 and MMP-9, while the corresponding levels
of the cleaved/inactive form were reduced. Further, although
TNF-a is a potent inducer of chemokine secretion by WT astro-
cytes, TNF-a stimulation of DKO astrocytes could not promote
T cell transmigration, and the pro-migration effects of TNF-a/
IL-17 and the suppressive effects of IFN-g were ablated by the
inhibition of MMP-2 and MMP-9 and did not strictly correlate
with chemokine levels. We showed here that CXCL12 is present
in perivascular cuffs of postcapillary venules in the active/un-
cleaved form, thereby retaining leukocytes in the cuff (McCand-
less et al., 2006) and probably accounting for the enlarged cuffs
observed in the MMP chimeric mice. However, CXCL12 that is
expressed or diffuses toward the cuff border and into the CNS
parenchyma is inactivated due to the presence of activated
MMP-2/9, permitting leukocytes to respond to other chemo-
kines, such as CXCL10, which we showed are localized outside
of the cuff and strongly upregulated by MMP-2/9, but not other-
wise modulated by MMP-2/9.
Other chemokines such as CCL3 and CCL2 that are abundant
in the inflamed CNS are also cleaved by MMP-2/9, resulting in
fragments that bind antagonistically to their receptors (McQuib-
ban et al., 2000, 2002). Given the broad spectrum of chemokines
that are expressed simultaneously in the CNS during EAE, and
the varied effects of MMP-2/9 on the different chemokines, it is
likely that the sum of these effects determines whether or not
the disease-inducing T cells can breach the inflammatory front
to induce EAE symptoms. This highlights the strength of a func-
tional readout, as used here, to evaluate chemotactic potential.
In conclusion, during inflammation TNF-a and IL-1 versus
IFN-g and IL-17 balance leukocyte migration through induction
and/or inhibition of chemokines. We demonstrated that their
chemotactic effects are mediated, at least in part, by MMP-9
and MMP-2, and localized these effects to the inflammatoryCell Rfront. Our data illustrate that the cytokine-MMP-chemokine
axis defines a network that governs whether or not leukocytes
can breach the inflammatory front to transmigrate the paren-
chymal border and induce disease symptoms. Rather than a sin-
gle cytokine, the ratio of stimulatory and regulatory cytokines
orchestrates leukocyte movement across the parenchymal bar-
rier, features that are relevant to other inflammatory conditions.
Although previous studies have implicated MMP-2/9 in EAE
and human MS, our data demonstrate that it is not MMP activity
per se but rather its in vivo localization that is crucial. The activa-
tion of MMP-2/9 precisely at the parenchymal border by cyto-
kines, and, thereby, activation of chemotactic signals at this
border, means that, once the leukocytes have transmigrated
across the parenchymal border and entered into the CNS paren-
chyma, the cytokine levels decrease and the chemotactic signal
is switched off. This provides initially a self-perpetuating system
that then becomes self-limiting, simply by the migration of the
leukocytes across the parenchymal border into the CNS paren-
chyma, amechanism that would not require high MMP levels but
rather depends on the strategic localization of actived MMPs.
EXPERIMENTAL PROCEDURES
Animals
Mice employed were C57BL/6, Tnf–/– (Ko¨rner et al., 1997),Mmp2–/– (Itoh et al.,
1997), Mmp9–/– (Dubois et al., 1999), Notch-1-loxP (Radtke et al., 1999), and
dystroglycan-loxP mice (Moore et al., 2002). Mmp2–/– and Mmp9–/– mice
were bred to generate double KO (DKO) and heterozygous littermate controls.
Experiments were conducted according to German Animal Welfare guidelines.
Antibodies
Antibodies used in immunofluorescence, flow cytometry, and cell sorting were
from BD Pharmingen or eBioscience unless otherwise stated: pan-laminin
(455), CD45 (30G.12), CD45.2 (104), CD45.1 (A20), CD11b/MAC-1 (M1/70),
CD4 (H129.19), Foxp3 (NRRF-30), IL-17 (TC11-18H10.1), IFN-g (XMG1.2),
IL-6 (MP5-20F3), IL-10 (JES5-16E3), IL-4 (11B11), IL-2 (JES6-5H4), TNF-a
(MP6-XT22) and CD16/CD32 (2.4G2), myelin basic protein (PA1050, Boster
Biological Technology) and glial-fibrillar-acidic protein (G-A-5, Sigma-Aldrich),
CXCL12 (AHP794, AbD Serotec), CXCL10 (AF-466, R&D Systems), CCL3
(ab25128, Abcam), and dystroglycan (Vimsa) (Agrawal et al., 2006).
Immunohistochemistry
Immunofluorescence stainings were performed as described previously
(Agrawal et al., 2006). To measure cuff sizes, brains and spinal cords were ori-
ented in the same position and sectioned entirely from dorsal to ventral. Bound
antibodies were visualized using Alexa 488- or Cy3-conjugated goat anti-rat,
Cy3- or Cy5-conjugated anti-rabbit secondary antibodies (Jackson ImmunoR-
esearch Laboratories and Molecular Probes), and FITC-anti-CD45 (104, eBio-
science). Sections were examined using a Zeiss AxioImager equipped with
epifluorescent optics or a Zeiss LSM 700 confocal microscope, and docu-
mented using a Hamamatsu ORCA ER camera.
Stainings for CXCL10 required fixation of whole brains in 4% paraformalde-
hyde (PFA) for 90 min at 4C, embedding in 4% agarose, and sectioning into
200-mm sections. Sections were blocked in 4% normal goat serum plus 3%
BSA in 0.5% Triton X-100. Primary and secondary antibody incubations
were performed overnight at 4C. Stainings for CCL3 and the cleaved form
of CXCL12 functioned only on 5–10-mm cryosections.
MMPs and Inhibitors
Recombinant MMPs were from R&D Systems. p-Aminophenylmercuric ace-
tate (APMA; Sigma-Aldrich) was used to activate MMP-1, MMP-7, and
MMP-8. MMP-3 was employed to activate MMP-2 and MMP-9. MOBSAM,
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a dose-dependent inhibitor of MMPs (Matsumura et al., 2005). qPCR for
MMP-2 andMMP-9mRNAs was performed using primers listed in the Supple-
mental Experimental Procedures.
Active and Passive EAE
EAE was induced using 35–55 peptide of myelin oligodendrocyte glycoprotein
(MOG35–55). Passive transfer of encephalitogenic T cells was as described pre-
viously (Wu et al., 2009). EAE onset was defined by weight loss and appear-
ance of a limp tail. Peak EAE was between days 20 and 25 after immunization
or T cell transfer.
BM Chimeric Mice
WT or DKO BM cells were transferred i.v. (5 3 106 per mouse) to lethally irra-
diated (11 Gy) congenic recipients (WT, Mmp2–/–, Mmp9–/–, or DKO mice).
Polymorphic lineage determinants (CD45.1/CD45.2) were used for tracking
donor- versus host-derived immune cells.
In Vitro T Cell Differentiation
MOG35–55-specific CD4
+ T cells were cultured in RPMI medium, 10%
FCS, and 20 mg/ml MOG35–55 for 2 days, and then in the presence of IL-2
(10 ng ml–1) for another 2 days. IL-12 (10 ng ml–1) and anti-IL-4 (10 mg ml–1)
were added for TH1 differentiation, or IL-23 (10 ng ml
–1), IL-1b (10 ng ml–1),
anti-IFN-g (10 mg ml–1), and anti-IL-4 (10 mg ml–1) for TH17 differentiation,
and cultured for another 5 days.
MRI
MRI measurements to determine brain volumes were performed before and
after EAE on a 3T Philips Achieva System (Philips Healthcare) equipped with
a 4-cm solenoidal radio frequency coil with heater to maintain body tempera-
ture. Mice were anaesthetized by continuous inhalation of 1.5% isofluorane.
No gating or triggering during the measurements was used. A 3D gradient
echo dataset was acquired in 9:50-min scan time using the following parame-
ters: isotropic resolution, 200 mm, reconstructed to 903 903 200 mm3; field of
view (FOV), 20 3 16 3 8 mm3; echo time/repetition time (TE/TR), 5.1/18 ms;
excitation pulse angle, 35; averages, 10. The brain was segmented semi-
manually using the lasso-tool in the software package amira (Visage Imaging),
and the volume was calculated.
Stereology
Following MRI, brains and spinal cords were excised, weighed, and sectioned
entirely (ventral to dorsal; approximately 1,000 sections of 5–6 mm/brain); 1 in
every 50 sections were stained for CD45 and pan-laminin, and cuff numbers
and areas weremeasured using Volocity 5.5 (Improvision). At least four individ-
ual mice per group (i.e., WT, Tnf–/–, DKOmice transferred withWT T cells) were
analyzed.
In Situ Hybridization
Frozen sections of EAE brains were fixed in 4% PFA and in situ hybridization
was performed as described previously (Frieser et al., 1997), with the exception
that riboprobes were labeled with digoxigenin (DIG)-UTP and detected by
sheep anti-digoxygenin alkaline phosphatase, followed by alkaline phospha-
tase reaction using nitrotetrazolium blue chloride and 5-bromo-4-chloro-3-in-
dolyl. After in situ hybridization, sections were stained with GFAP-Cy3
(Sigma-Aldrich) and DAPI, and imaged using a Zeiss AxioImager. The 385-bp
mouse MMP-9 cDNA was generated by PCR using the following primers:
50CATTCGCGTGGATAAGGA30 and 50ACAAGAAAGGACGGTGGG 30.
Cytometric Bead Array
CD4+ T cells (23 105) were cultured in RPMImediumwithMOG35–55 for 2 days
as described above, and cytokine levels in conditioned media were measured
using Cytomix kit (Bender MedSystems). All chemokines, except CCL20 and
CXCL12, in tissue extracts and conditioned media were measured using Che-
momix kit (Bender MedSystems).
ELISA
Full-length CXCL12 was measured using the mouse CXCL12/SDF-1 alpha
Quantikine ELISA kit (R&D); for cleaved CXCL12, the primary antibody was re-1052 Cell Reports 10, 1040–1054, February 24, 2015 ª2015 The Authplaced by anti-CXCL12 5-67 (Vergote et al., 2006) and data were expressed as
OD450 values. CCL20 levels were measured using mouse CCL20 Quantikine
ELISA kit (R&D). MMP-2 and MMP-9 activities were measured using the
QuickZyme kit (QuickZyme Biosciences).
Flow Cytometry
Mice were perfused with PBS before spleens, LNs, and brains were harvested.
Spleens and brains were treatedwith 2 mgml–1 collagenase D (Roche Diagnos-
tics) and 1 mg ml–1 DNase I (Roche Diagnostics), and cells were isolated by cell
straining (70 mm spleens/100 mm brains). Brain homogenates were separated
into neuronal and leukocyte populations by discontinuous density gradient
centrifugation using isotonic Percoll (Amersham). The intracellular staining
kit (eBioscience) was employed to permeabilize and fix cells, and flow cytom-
etry was performed using a FACS Calibur (Becton Dickinson). Delta-like pro-
tein/Fc chimera (R&D) and TRITC-labeled goat anti-mouse IgG Fc (Jackson
ImmunoResearch) were employed in flow cytometry for detection of astrocyte
expression of Notch-1.
Gelatin Zymography
Gelatin gel and in situ zymography coupled with immunofluorescence staining
were performed as described previously (Agrawal et al., 2006), with the ex-
ception that centrifugation concentrated (Amicon) and gelatin-Sepharose
prepurified astrocyte condition media were employed in gel zymography.
Conditioned media from confluent 48-hr cultures were pooled, concentrated,
and purified before use in gel zymography.
Astrocyte Culture
Primary astrocyte cultures were prepared from brains of newborn WT,
Mmp2–/–, Mmp9–/–, and DKO mice as described previously (Agrawal et al.,
2006). Serum-free F12 medium from astrocyte cultures was collected at
24–48 hr for use in in vitro transmigration assays, gel zymography, and chemo-
kine secretion measurements. In some cases, astrocytes were cultured over-
night in serum-free F12 plus TNF-a (50 ng ml–1); IFN-g (300 unit ml–1); IL-17
(500 ng ml–1); recombinant activated MMP-2 (100 ng ml–1) and/or MMP-9
(20 ng ml–1); or 10, 50, or 150 nM MOBSAM.
Astrocytes were isolated from newborn Notch-1-loxP and dystroglycan-
loxPmice. Cells were treated with 2 mM recombinant cre-recombinase protein
(HTNC) for 20 hr, washed, and cultured in F12 medium for 1 week before
testing by flow cytometry using anti-b-dystroglycan antibody or Delta-like pro-
tein/Fc chimera plus TRITC-labeled goat anti-mouse IgG Fc.
Transmigration Assays
Transmigration studies were performed with T cells isolated from spleens and
LNs at day 14 or 17 after EAE induction using anti-CD4-coated MACS beads.
Cells (0.73 106) in 100 ml serum-free DMEMwere placed in the upper chamber
of a transwell filter (Costar, 5 mm), and transmigration was induced by adding
600 ml serum-free F12 astrocyte-conditioned medium to the lower chamber,
0.1–1 mg ml1 recombinant chemokines (CXCL12, CXCL10, CCL21) (Promo-
kine) alone, or chemokines plus activated MMP-2 or MMP-9. Experiments
were conducted at 37C for 6 hr, after which the number of cells that had trans-
migrated into the lower chamber were counted and expressed as a percent-
age of the total cells added.
Notch-1 Signaling
qPCR was used to determine mRNA expression of Hes-1 and Hes-5 using the
primers listed in the Supplemental Experimental Procedures. For Notch-1-
signaling experiments, astrocytes were untreated or treated for 24 hr with
50 ng ml–1 TNF-a and recombinant activated MMP-2 or MMP-9. Cells were
lysed and analyzed by western blotting using the following antibodies: PTEN
(D4.3, Cell Signaling Technology), p65 (C22B4, Cell Signaling Technology),
Phospho-NF-kB p65 (93H1, Cell Signaling Technology), Phospho-IkB-a
(14D4, Cell Signaling Technology), Phospho-AKT (Biosource), total Akt
(C67E7, Cell Signaling Technology), and b-Tubulin (Epitomics).
Statistical Analyses
Statistical analyses were performed using GraphPad Prism. All values are ex-
pressed asmeans±SEM.Datawere tested for normality (Kolmogorov-Smirnovors
test in GraphPad Prism). If there was no normal distribution, then we used the
non-parametric Mann-Whitney or Kruskal-Wallis test, otherwise we employed
the two-sided Student’s t test or ANOVA.
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